tiprankstipranks
Replimune Group Inc (DE:7R8)
MUNICH:7R8

Replimune Group Stock Price & Analysis

0 Followers

7R8 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€17.5
Volume0.00
Average Volume (3M)325.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€244.65M
Total Debt (Recent Filing)€32.20M
P/E RatioN/A
Beta0.40
Next EarningsNov 14, 2022
EPS Estimate-€0.77
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares OutstandingN/A
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume325
P/B RatioN/A
P/S RatioN/A
P/CF RatioN/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside142.04% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

7R8 FAQ

What was Replimune Group’s price range in the past 12 months?
Currently, no data Available
What is Replimune Group’s market cap?
Currently, no data Available
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Nov 14, 2022 which is in 38 days.
    How were Replimune Group’s earnings last quarter?
    Replimune Group released its earnings results on Aug 04, 2022. The company reported -€0.796 earnings per share for the quarter, missing the consensus estimate of -€0.616 by -€0.18.
      Is Replimune Group overvalued?
      According to Wall Street analysts Replimune Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Replimune Group pay dividends?
        Replimune Group does not currently pay dividends.
        What is Replimune Group’s EPS estimate?
        Replimune Group’s EPS estimate is -€0.77.
          How many shares outstanding does Replimune Group have?
          Currently, no data Available
          What happened to Replimune Group’s price movement after its last earnings report?
          Replimune Group reported an EPS of -€0.796 in its last earnings report, missing expectations of -€0.616. Following the earnings report the stock price went up 3.109%.
            Which hedge fund is a major shareholder of Replimune Group?
            Among the largest hedge funds holding Replimune Group’s share is Omega Fund Management, LLC. It holds Replimune Group’s shares valued at 82M.

              ---

              Replimune Group Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              7

              Analyst Consensus

              Strong Buy
              Average Price Target: €42.36

              Blogger Sentiment

              Bullish
              DE:7R8 Sentiment 100% Sector Average 71%

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              Neutral
              Bullish 50% Bearish 50%

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -39.10%
              12-Months-Change

              Fundamentals

              Return on Equity
              -29.91%
              Trailing 12-Months
              Asset Growth
              -12.28%
              Trailing 12-Months
              The Replimune Group Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Replimune Group Inc

              Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis